Overview
David Ridley, PhD, is a health economist at Duke University's Fuqua School of Business. His research focuses on incentives for innovation and quality, as well as pricing. He is dedicated to creating and studying tools that improve health.
David was the lead author of two papers that became law. He and his colleagues proposed the Food and Drug Administration (FDA) priority review voucher program which became law in 2007. The vouchers provide incentives for drug development for neglected and rare diseases. The FDA has awarded more than 90 vouchers valued at about $100 million each. David and his colleagues also proposed the Environmental Protection Agency vector expedited review voucher program which became law in 2022.
David has served for more than a decade as the Faculty Director of the Center for Health Sector Management (HSM). HSM students comprise about 20 percent of Duke MBA graduates each year.
David's primary appointment is at the business school with honorary appointments in the Department of Economics and Sanford School of Public Policy. He also serves on the executive faculty committee of the Duke-Margolis Institute for Health Policy.
Current Duke Appointments & Affiliations
Recent Scholarly Works
Conditional and Lenient Drug Approvals
Journal article Management Science · October 19, 2026 Firms are often allowed to sell new drugs based on preliminary efficacy evidence, with final approval contingent on confirmatory testing. We characterize optimal approval policies for a government agency that maximizes consumer welfare while consid ... Full text CiteThe value of speed for drug developers.
Journal article Nat Rev Drug Discov · September 18, 2026 Full text Link to item CiteEuropean priority review vouchers for neglected disease product development.
Journal article BMJ global health · January 2024 IntroductionNeglected diseases are a significant global health challenge. Encouraging the development of therapeutics and vaccines for these diseases would address an important unmet medical need. We propose a priority review voucher programme for ... Full text CiteRecent Grants
The Commercial Value of Pull Mechanisms for Drug Development in Neglected Tropical Diseases
ResearchPrincipal Investigator · Awarded by Bill and Melinda Gates Foundation · 2024 - 2026The Next Phase of Antimicrobial Resistance Payment Policy
ResearchFaculty Member · Awarded by Wellcome Trust · 2022 - 2023Transferable Exclusivity Voucher (TEV) Program for Neglected Diseases (Phase 3 Supplement)
ResearchPrincipal Investigator · Awarded by Bill and Melinda Gates Foundation · 2018 - 2022View All Grants